You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Financement des régimes fondés sur les données probantes

Les monographies et fiches d’information sur les médicaments et les régimes à l’intention des patients offrent des renseignements sur la posologie et l’administration des traitements contre le cancer.

Elles ne sont fournies qu’à titre indicatif et ne visent pas à remplacer les renseignements posologiques ni les recommandations d’un médecin.

Si vous avez des questions à propos du financement des TS-PBQ, veuillez consulter la Foire aux questions (anglais) de notre site Web.

Découvrez les fiches d’information améliorées sur les régimes à l’intention des patients, élaborées en collaboration avec les conseillers des patients et des familles. Disponible en français.

Regimens

15 Items
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Drugs Used:
topotecan (Unfunded),
May 2019
Cancer Type: Sarcoma, Ewing's, Soft Tissue     
Intent: Palliative
Feb 2018
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Aug 2019
Cancer Type: Gastrointestinal, Hepatobiliary / Liver / Bile Duct     
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Advanced hepatocellular carcinoma, with specific criteria
Jun 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Metastatic renal cell carcinoma of clear cell histology as second-line treatment, with specific criteria
Aug 2019
Cancer Type: Endocrine, Thyroid     
Intent: Palliative
Drugs Used:
SORAfenib (Unfunded)
Jun 2019
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Curative
Drugs Used:
SORAfenib (Unfunded)
Jun 2019
Cancer Type: Gastrointestinal, Gastrointestinal Stromal Tumours, Sarcoma, GIST     
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
Jun 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Metastatic renal cell carcinoma, with specific criteria
Aug 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumours (pNET), according to specific criteria
Jun 2019
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Funding:
New Drug Funding Program
    Topotecan - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Topotecan - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Aug 2017
Cancer Type: Lung, Small Cell     
Intent: Palliative
Drugs Used:
topotecan (Unfunded)
Dec 2017